The 8th ISCC

December 1 -2, 2003
Keidanren Hall

December 1, 2003 (Mon)

13:00–13:10

Haruo Sugano (Cancer Chemotherapy Center, Tokyo)

Welcome and Introduction

From Human Genome to Cancer Chemotherapy

Chairpersons: Robert H. Shoemaker (NCI-Frederick, USA)
Takashi Tsuruo (Univ. Tokyo, Tokyo)

13:10–13:40

Jaap Verweij (Erasmus University Medical Center, Netherlands)

Is phenotype/genotype based dosing for irinotecan a feasible way of

dose-individualisation?

13:40–14:00

Saburo Sone (Univ. Tokushima, Tokushima) and Yusuke Nakamura (Univ. Tokyo, Tokyo)

Genetic predictor of EGF receptor-targeted therapy for non-small cell lung cancer

14:00–14:30

Yoshiji Fujita (Tokyo Medical University, Tokyo)

Proteome analysis of anticancer drug response

14:30–14:40

Discussion

14:40–15:00

Coffee Break

Molecular Targets in Cancer Chemotherapy (Part I)

Chairpersons: Jaap Verweij (Erasmus University Medical Center, Netherlands)
Yoshimasa Uehara (National Institute of Infectious Diseases, Tokyo)

15:00–15:30

Herbert M. Pinedo (VUmc Cancer Center Amsterdam, Netherlands)

Anti-VEGF drugs

15:30–15:50

Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)

VEGFR2 inhibitor

15:50–16:20

Johann de Bono (Royal Marsden Hospital, UK)

Targeted therapy for the treatment of prostate cancer

16:20–16:50

Jean-Pierre Armand (Institut Gustave Roussy, France)

Sugen 11248

16:50–17:20

Joseph P. Eder (Dana-Farber Cancer Institute, USA)

Anti-angiogenic targets in drug development: target validation in clinical trials

17:20–17:30

Discussion

17:30–18:30

Mixer

December 2, 2003 (Tue)

Molecular Targets in Cancer Chemotherapy (Part II)

Chairpersons: Mace L. Rothenberg (Vanderbilt University Medical Center, USA)
Ryuzo Ueda (Nagoya City Univ., Nagoya)

09:30–10:00

Robert H. Shoemaker (NCI-Frederick, USA)

Targeting transcription factors for cancer chemotherapy

10:00–10:30

Edward A. Sausville (DTP, NCI, USA)

Approaches to histone deacetylase inhibition and DNA methylation

10:30–11:00

Nagahiro Saijo (National Cancer Center Hospital, Tokyo)

What are problems for the negative phase III trials of molecular target based drugs?

11:00–11:10

Discussion

11:10–11:30

Coffee Break

New Drugs under Clinical Consideration (Part I)

Chairpersons: Herbert M. Pinedo (VUmc Cancer Center Amsterdam, Netherlands)
Masahiro Fukuoka (Kinki Univ., Osaka)

11:30–11:50

Noboru Yamamoto (National Cancer Center Hospital, Tokyo)

ZD6474

11:50–12:20

Jeanette Wood (Novartis Pharma AG, Switzerland)

From drug discovery to the clinic; experiences with PTK787/ZK222584, a VEGF receptor tyrosine kinase inhibitor

12:20–12:50

Nikhil C. Munshi (Dana-Farber Cancer Institute, USA)

Thalidomide analogues

12:50–13:00

Discussion

13:00–14:00

Lunch Break

New Drugs under Clinical Consideration (Part II)

Chairpersons: Jean-Pierre Armand (Institut Gustave Roussy, France)
Yoshiro Niitsu (Sapporo Medical Univ., Sapporo)

14:00–14:20

Hironobu Minami (National Cancer Center Hospital East, Kashiwa)

Raf kinase inhibitor, BAY 43-9006

14:20–14:50

Xiongwen Zhang (Shanghai Institute of Materia Medica, China)

Salvicine, a novel DNA topoisomerase inhibitor showing potent anti-MDR effect

14:50–15:10

Hideyuki Akaza (Univ. Tsukuba, Tsukuba)

Selective endothelin receptor antagonist for prostate cancer; a clinical aspect

15:10–15:40

Matthias Mueser (Merck KGaA, Germany)

The epidermal growth factor receptor-targeting monoclonal antibody/cetuximab in the treatment of cancer

15:40–15:50

Discussion

15:50–16:10

Coffee Break

Clinical Development of Anticancer Agents

Chairpersons: Edward A. Sausville (DTP, NCI, USA)
Yutaka Ariyoshi (Aichi Hosp., Nagoya)

16:10–16:40

Yasuhiro Fujiwara (National Cancer Center Hospital, Tokyo)

The impact of the 2002 revision of Pharmaceutical Affairs Law : Introduction of investigator-initiated registration-directed clinical trials in Japan

16:40–17:10

Mace L. Rothenberg (Vanderbilt University Medical Center, USA)

Clinical development of molecular-targeted agents: challenges and opportunities

17:10–17:20

Discussion

17:20–17:30

Takashi Tsuruo (Univ. Tokyo, Tokyo)

Closing Remark

Page TOP